These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28903328)

  • 1. CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.
    Chen WL; Huang AF; Huang SM; Ho CL; Chang YL; Chan JY
    Oncotarget; 2017 Aug; 8(33):54115-54135. PubMed ID: 28903328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo.
    Tang J; Zhang L; She X; Zhou G; Yu F; Xiang J; Li G
    Cancer Invest; 2012 Jun; 30(5):380-9. PubMed ID: 22409183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD164 regulates proliferation, progression, and invasion of human glioblastoma cells.
    Wang CC; Hueng DY; Huang AF; Chen WL; Huang SM; Yi-Hsin Chan J
    Oncotarget; 2019 Mar; 10(21):2041-2054. PubMed ID: 31007847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis.
    Havens AM; Jung Y; Sun YX; Wang J; Shah RB; Bühring HJ; Pienta KJ; Taichman RS
    BMC Cancer; 2006 Jul; 6():195. PubMed ID: 16859559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma.
    Tu M; Cai L; Zheng W; Su Z; Chen Y; Qi S
    Mol Med Rep; 2017 Apr; 15(4):1713-1721. PubMed ID: 28259931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
    Lennon FE; Mirzapoiazova T; Mambetsariev B; Salgia R; Moss J; Singleton PA
    Anesthesiology; 2012 Apr; 116(4):857-67. PubMed ID: 22343475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin.
    Chung LY; Tang SJ; Wu YC; Sun GH; Liu HY; Sun KH
    Oncotarget; 2015 Mar; 6(7):4936-52. PubMed ID: 25669973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
    Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
    Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer.
    Chou YT; Lee CC; Hsiao SH; Lin SE; Lin SC; Chung CH; Chung CH; Kao YR; Wang YH; Chen CT; Wei YH; Wu CW
    Stem Cells; 2013 Dec; 31(12):2607-19. PubMed ID: 23940081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.